BinaxNow™ Rapid Test

Overview

About this study

The purpose of this study is to validate the BinaxNOW™ COVID-19 Ag Card in the asymptomatic COVID-19 screening population.

The BinaxNOW™ COVID-19 Ag Card is a useful tool for the rapid detection of SARS-CoV-2 and screening for COVID-19 in both symptomatic and asymptomatic patient populations.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adults ≥ 18 years of age.
Asymptomatic subjects presenting for SARS-CoV-2 screening as part of their routine pre-procedural testing.

Exclusion Criteria:

Individuals < 18 years of age.
Symptomatic subjects.
Subjects who are not undergoing routine SARS-CoV-2 PCR screening.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Matthew Binnicker, Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Binnicker, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials